Loading clinical trials...
Loading clinical trials...
Finnish Venous Ulcer Study
This multicenter randomized controlled trial evaluates the effect of first-visit foam sclerotherapy (including sub-ulcer foam sclerotherapy) in patients with venous leg ulcer.
To evaluate the effect of first-visit foam sclerotherapy, patients with venous leg ulcers are randomly assigned to either the first-visit foam sclerotherapy group or the scheduled treatment group. The scheduled treatment group represents the current standard of care. The primary outcome of this study is the time to ulcer healing. In addition to the first-visit treatment in the study group, both groups receive endothermal ablation and/or foam sclerotherapy to (further) treat ulcer-related insufficient veins and truncal insufficiency in scheduled treatment visit(s). Class 2 thigh-high compression or the best possible compression therapy tolerated by the patient is provided in both groups. The follow-up period for the primary outcome is one year. For this study, based on Oulu University Hospital's retrospective data (partly published in Pihlaja et al 2020) of venous ulcer healing the investigators assumed Hazard Ratio 1.5 for venous ulcer to heal in first-visit foam sclerotherapy group compared to scheduled treatment group. Assuming drop-out of 10% this study recruits total of 248 patients (a=0.05, b=0.2).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Helsinki University Central Hospital
Helsinki, Finland
Keski-Suomen keskussairaala
Jyväskylä, Finland
Oulu University Hospital
Oulu, Finland
Turku University Hospital
Turku, Finland
Vaasa Central Hospital
Vaasa, Finland
Start Date
February 26, 2021
Primary Completion Date
March 1, 2025
Completion Date
March 1, 2026
Last Updated
January 15, 2025
248
ESTIMATED participants
Endothermal Ablation
PROCEDURE
Foam Sclerotherapy
PROCEDURE
Lead Sponsor
Oulu University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions